Company profile
BioCryst Pharmaceuticals, Inc.
NASDAQ: BCRX · Healthcare · Biotechnology
#165 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
76B+FH 69DQ 91GM 60SS 87
v0.1 · 65/100 weight · provisional
↑ operating margin, return on assets · ↓ growth stability, balance-sheet leverage
Methodology →Revenue TTM
$885.7M
Rev growth YoY (TTM)
+75.9%
Net income (FY)
$263.9M
Employees
435
as of 2026-08-09
Market cap
$2.4B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$874.8M$874.8M2025
Net income$263.9M$263.9M2025
Operating income$341.0M$341.0M2025
Total assets$514.2M$514.2M2025
Liabilities$633.3M$633.3M2025
Equity-$119.2M-$119.2M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product71%
License28%
Collaborative And Other Research And Development1%
By geography
Not disclosed.
The read
What is BioCryst Pharmaceuticals, Inc.’s revenue?
BioCryst Pharmaceuticals, Inc. booked $874.8M in FY2025 revenue, growing 94% year over year — faster than most Healthcare companies we track, at a 30.2% net margin.
Peers · Healthcare
Neogen Corporation65BANI Pharmaceuticals, Inc.82B+Nutex Health, Inc.68BHarmony Biosciences Holdings, Inc.76B+Innovage Holding Corp.68BVarex Imaging Corporation67BNeighbors
Durham →Key facts
CEOCharles K. Gayer
SectorHealthcare
IndustryBiotechnology
HeadquartersDurham, NC
ExchangeNASDAQ: BCRX
Employees435
IPO date1994-03-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.